A study presented at the Advanced Technologies and Treatments for Diabetes conference showed that type 1 diabetes patients who used the t:slim X2 Insulin Pump with Basal-IQ technology, a predictive low glucose suspend feature, experienced a significant reduction in hypoglycemic events, an improved time in range and reported a high level of confidence in using the device, compared with those who used a standard continuous glucose monitoring-integrated t:slim X2 pump that was not fitted with the automated insulin suspension. Researchers included 103 patients, ages 6 to 72, in the PROLOG trial.
Reduced hypoglycemia tied to use of insulin pump with Basal-IQ, study finds
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.